Clinical Trial Update: Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 open-label study of intravitreal ICON-1 in choroidal neovascularization due to age-related macular degeneration has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization
• Wet Macular Degeneration

Drugs mentioned

• ICON-1

Snippet

Sponsor: Iconic Therapeutics, Inc. | Conditions: Choroidal Neovascularization, Wet Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2021-03-15